TCS Industries Limited (China-sourced API supplier) supplies Milbemycin Oxime — API CAS 129496-10-2 for pharmaceutical B2B procurement — COA, MSDS, and technical documentation available on request.
> Overview
| Product Name | Milbemycin Oxime |
|---|---|
| Structural Formula |  |
| CAS Number | 129496-10-2 |
| Molecular Formula | C63H88N2O14 |
| Molecular Weight | 1097.4 g/mol |
| InChIKey | CKVMAPHTVCTEMM-ALPQRHTBSA-N |
| SMILES | Available on request where applicable |
| Appearance | White to yellowish crystalline powder |
| Purity / Grade | By agreed specification and batch COA |
| Storage | Store at controlled room temperature, protect from light |
Milbemycin Oxime (CAS 129496-10-2) is a macrocyclic lactone antiparasitic with the formula C₃₁H₄₃NO₇ (milbemycin A₃ oxime) / C₃₂H₄₅NO₇ (milbemycin A₄ oxime, MW ~557). It is produced by Streptomyces hygroscopicus aureolacrimosus. Milbemycin oxime potentiates glutamate-gated chloride channels in invertebrate neurons, causing paralysis. It is used for heartworm prevention, intestinal nematode treatment, and demodectic mange in dogs.
TCS Industries Limited, a Hong Kong-based trading and sourcing company, supplies Milbemycin Oxime API for veterinary chewable tablet and combination product formulation programs.
> Applications
Heartworm prevention in dogs and cats
Milbemycin Oxime is administered monthly as a chewable tablet for prevention of Dirofilaria immitis infection. Dosing in dogs is 0.5 mg/kg; in cats, 2 mg/kg. Commercial products include Interceptor (Elanco) and Sentinel (combination with lufenuron). The API is formulated into flavored chewable matrices with controlled disintegration for palatability and dose uniformity. McTier et al. (Am J Vet Res, 1992, 53:2126–2133) established the efficacy profile for milbemycin oxime in heartworm prevention.
Combination antiparasitic products
Milbemycin Oxime is combined with praziquantel (Milbemax / Interceptor Plus) for broad-spectrum coverage of nematodes, cestodes and heartworm in a single tablet. Combination formulations require compatibility studies and co-granulation or bilayer tablet design to ensure simultaneous dissolution and bioavailability of both actives.
> Sourcing & Supply
TCS Industries Limited supports development, qualification and commercial purchasing discussions for Milbemycin Oxime with buyers in Australia, New Zealand, Canada and South Korea.
- Development and qualification quantities: 100 g to 5 kg packs for formulation trials, analytical method validation, and veterinary drug registration submissions.
- Pallet quantities and production campaigns: repeat supply is coordinated against packaging, lead time, annual demand and destination-market import requirements.
> Quality & Documentation
Key specification parameters include assay (≥90.0% combined A₃ + A₄ oximes, ratio specified), related substances, loss on drying, residue on ignition, heavy metals, residual solvents, and microbial limits. White to yellowish crystalline powder. Practically insoluble in water, soluble in methanol and acetone. Identity by HPLC and IR. Meets in-house veterinary pharmaceutical specifications. COA and MSDS are standard.
> Packaging
Milbemycin oxime is a white to yellowish crystalline powder. Standard packaging includes sealed foil bags under nitrogen in fibre drums (50 g, 100 g, 500 g, or 1 kg). Store at controlled room temperature (15–25 °C). Protect from light and moisture. Shelf life is typically 36 months. Labels and documents are checked before dispatch.
> Pricing & MOQ
Pricing is quoted by specification, packaging and destination. Common commercial discussions use 25 kg bag/drum formats, pallet quantities and production-campaign planning; smaller samples may be reviewed for qualified formulation teams.
> Regulatory & Compounding Context
Milbemycin oxime is approved for veterinary use only. FDA-CVM approved in Interceptor (1990) and Sentinel (1995). EMA-authorized veterinary products. Not approved for human use. Multiple combination products approved globally. A₃:A₄ ratio specification varies by market and formulation.
> Alias Index
- Chemical name: Milbemycin oxime (A₃ + A₄ oxime mixture)
- CAS Number: 129496-10-2
- Formula: C₃₁H₄₃NO₇ / C₃₂H₄₅NO₇
- Brand names: Interceptor, Sentinel, Trifexis, Interceptor Plus
- ATCvet code: QP54AB02
- Source: Streptomyces hygroscopicus aureolacrimosus
- Commercial request terms: milbemycin oxime API, Interceptor generic, heartworm prevention API, macrocyclic lactone, TCS Industries Limited
> FAQ
What is the A3:A4 ratio specification for Milbemycin Oxime API?
Milbemycin Oxime is a defined mixture of milbemycin A3 oxime and milbemycin A4 oxime. The A4:A3 ratio is specified to match the originator product profile (typically 70–80% A4). This ratio affects regulatory equivalence for generic submissions. Specify the required ratio at inquiry.
What documents are available for Milbemycin Oxime orders?
COA and MSDS are standard for commercial discussions. COO, packing list, invoice and other import-support documents can be arranged according to order scope.
Do you supply Milbemycin Oxime to Australia and Canada?
Yes. We support B2B buyers in Australia, New Zealand, Canada and South Korea, subject to route and document review.
Do you supply New Zealand and South Korea?
Yes. We review Australia, New Zealand, Canada and South Korea for project supply, import documents, packaging and logistics planning before quotation.
Can Milbemycin Oxime be combined with other antiparasitics?
Yes. Milbemycin Oxime is commercially combined with praziquantel (Milbemax, Interceptor Plus) and with lufenuron (Sentinel). Compatibility, co-granulation and dissolution studies are required for combination products. TCS can source milbemycin oxime API alongside praziquantel for combination development programs.
What species are approved for Milbemycin Oxime treatment?
Milbemycin Oxime is approved for dogs and cats. It prevents heartworm (Dirofilaria immitis) and treats hookworm, roundworm and whipworm infections. Off-label use has been reported in some exotic species. Buyers should confirm local species-specific registration requirements.
Can you arrange samples before commercial purchasing?
Samples or evaluation quantities may be reviewed for qualified buyers after target specification, application and destination-market requirements are clarified.
How is Milbemycin Oxime packaged for export?
Packaging is confirmed by quantity and material properties. Typical options include foil bags, HDPE containers, fibre drums, 25 kg bags or palletized export packaging.
Can buyer-defined specifications be reviewed?
Yes. Send the specification, methods, impurity limits and required documents. TCS can review feasibility before confirming quotation and lead time.
What payment terms are normally used?
Standard payment is 100% T/T before dispatch unless a different arrangement has been approved for an established commercial account.
What lead time should buyers expect?
Lead time depends on stock, batch size, document scope and destination. Available stock can move faster; made-to-order or pallet programs require longer planning.
What is the difference between Milbemycin Oxime and Ivermectin?
Both are macrocyclic lactone endectocides but from different subclasses. Milbemycin Oxime is a milbemycin (CAS 129496-10-2); Ivermectin is an avermectin (CAS 70288-86-7). Milbemycin Oxime has a wider safety margin in ivermectin-sensitive breeds (e.g., Collies with MDR1 mutation), making it preferred for heartworm prevention in these breeds.
Last reviewed: June 2026
Evaluation and research orders (≤10 kg) are shipped with COA, MSDS, and certificate of origin. Bulk commercial orders (>10 kg) qualify for volume pricing with a full technical documentation package available on request.
> Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.